Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?

Teo, Andrew; Tan, Hao Dong; Loy, Thomas; Chia, Po Ying; Chua, Caroline Lin Lin

doi:10.1371/journal.ppat.1011223

Cited by 24 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study predicted an estimated 40 million people had been infected with DENV nationally, with 2.4 million annual infections ( Salje et al 2019 ). Thus, any subsequent infections raise the risk of developing severe dengue hemorrhagic fever through antibody-dependent enhancement (ADE) ( Teo et al 2023 ). The deaths of many people in 2022 when DENV-4 was introduced were probably associated with secondary and/or tertiary DENV infection ( Haider et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two decades of endemic dengue in Bangladesh (2000–2022): trends, seasonality, and impact of temperature and rainfall patterns on transmission dynamics

Hasan,

Khalil,

Chowdhury

et al. 2024

Journal of Medical Entomology

View full text Add to dashboard Cite

The objectives of this study were to compare dengue virus (DENV) cases, deaths, case-fatality ratio [CFR], and meteorological parameters between the first and the recent decades of this century (2000–2010 vs. 2011–2022) and to describe the trends, seasonality, and impact of change of temperature and rainfall patterns on transmission dynamics of dengue in Bangladesh. For the period 2000–2022, dengue cases and death data from Bangladesh’s Ministry of Health and Family Welfare’s website, and meteorological data from the Bangladesh Meteorological Department were analyzed. A Poisson regression model was performed to identify the impact of meteorological parameters on the monthly dengue cases. A forecast of dengue cases was performed using an autoregressive integrated moving average model. Over the past 23 yr, a total of 244,246 dengue cases were reported including 849 deaths (CFR = 0.35%). The mean annual number of dengue cases increased 8 times during the second decade, with 2,216 cases during 2000–2010 vs. 18,321 cases during 2011–2022. The mean annual number of deaths doubled (21 vs. 46), but the overall CFR has decreased by one-third (0.69% vs. 0.23%). Concurrently, the annual mean temperature increased by 0.49 °C, and rainfall decreased by 314 mm with altered precipitation seasonality. Monthly mean temperature (Incidence risk ratio [IRR]: 1.26), first-lagged rainfall (IRR: 1.08), and second-lagged rainfall (IRR: 1.17) were significantly associated with monthly dengue cases. The increased local temperature and changes in rainfall seasonality might have contributed to the increased dengue cases in Bangladesh.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Most infections (>80%) are self-limiting with no or mild clinical manifestation resulting in lifelong immunity for that serotype ( WHO-Bangladesh 2022 ). However, reinfection with different serotypes, known as secondary or tertiary dengue infection, may result in severe dengue with an increasing risk of fatal outcome ( Teo et al 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Two decades of endemic dengue in Bangladesh (2000–2022): trends, seasonality, and impact of temperature and rainfall patterns on transmission dynamics

Hasan,

Khalil,

Chowdhury

et al. 2024

Journal of Medical Entomology

View full text Add to dashboard Cite

show abstract

“…It is a known fact that pre-existing Abs present in the serum from a primary DV infection, bind to the infecting DV particles during a subsequent infection with a different serotype and can lead to an overall increase in the viral replication. This phenomenon is known as antibody-dependent enhancement (ADE) [40][41][42] . Again, ADE can also be observed between members of the same family of viruses.…”

Section: Discussionmentioning

confidence: 99%

Pre-dominance of dengue non-cross-reacting SARS-CoV-2 spike antibodies during the Omicron era and their role in the ADE-mediated surge of Dengue virus serotype 3

Sarker,

Dutta,

Mallick

et al. 2023

Preprint

View full text Add to dashboard Cite

In India, the SARS-CoV-2 Delta wave (2020-21) gradually faded away with the advent of the Omicron variants (2021-present). Dengue incidences were observably less in Southeast Asia during the active years of the pandemic (2020-21). However, Dengue virus type 3 (DV3) cases were increasingly reported in India and many other dengue-endemic countries concurrent with the progression of the Omicron wave since 2022. This observation prompted us to investigate the current state of cross-reactivity between prevalent SARS-CoV-2 variants and different DV serotypes.Fifty-five COVID-19 serum samples (collected between January-September, 2022) and three pre-pandemic healthy serum samples were tested for DV or SARS-CoV-2 Immunoglobulin G/Immunoglobulin M (IgG/IgM) using the lateral flow immunoassays (LFIAs). The SARS-CoV-2 antibody (Ab)-positive samples were further tested for their ability to cross-neutralize DV types 1-4 (DV1-4) in Huh7 cell lines.Cross-reactivity between SARS-CoV-2 and DV diminished with the shift from Delta to Omicron prevalence. COVID-19 serum samples that were DV cross-reactive neutralized all DV serotypes, including DV3. However, Omicron wave serum samples were predominantly DV non-cross-reactive (about 70%) in LFIAs and coincided with the prevalence of BA.2 Omicron variant. They also cross-neutralized DV1, 2 and 4 but enhanced DV3 infectivity as evident from increased DV3 titres in virus neutralization test (VNT) compared to control serum samples.In conclusion, DV non-cross-reactive COVID-19 serum samples are becoming increasingly prominent in the present times. These non-cross-reactive serums could neutralize DV1, 2 and 4 but they are contributing to the surge in DV3 cases worldwide by means of ADE.

show abstract

“…Other symptoms may include a severe headache, abdominal pain, skin rash, muscular fatigue, joint pain, loss of appetite, vomiting, diarrhea, and an unpleasant taste. Additionally, the viral infection may produce impaired physical and cognitive development [ 2 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Tracing down the Updates on Dengue Virus—Molecular Biology, Antivirals, and Vaccine Strategies

Malik¹,

Ahsan

Mumtaz

et al. 2023

Vaccines

View full text Add to dashboard Cite

Background: Nearly half of the world is at risk of developing dengue infection. Dengue virus is the causative agent behind this public healthcare concern. Millions of dengue cases are reported every year, leading to thousands of deaths. The scientific community is working to develop effective therapeutic strategies in the form of vaccines and antiviral drugs against dengue. Methods: In this review, a methodological approach has been used to gather data from the past five years to include the latest developments against the dengue virus. Results: Different therapeutics and antiviral targets against the dengue virus are at different stages of development, but none have been approved by the FDA. Moreover, various vaccination strategies have also been discussed, including attenuated virus vaccines, recombinant subunit vaccines, viral vector vaccines, DNA vaccines, nanotechnology, and plant-based vaccines, which are used to develop effective vaccines for the dengue virus. Many dengue vaccines pass the initial phases of evaluation, but only two vaccines have been approved for public use. DENGVAXIA is the only FDA-approved vaccine against all four stereotypes of the dengue virus, but it is licensed for use only in individuals 6–16 years of age with laboratory-confirmed previous dengue infection and living in endemic countries. Takeda is the second vaccine approved for use in the European Union, the United Kingdom, Brazil, Argentina, Indonesia, and Thailand. It produced sustained antibody responses against all four serotypes of dengue virus, regardless of previous exposure and dosing schedule. Other dengue vaccine candidates at different stages of development are TV-003/005, TDENV PIV, V180, and some DNA vaccines. Conclusion: There is a need to put more effort into developing effective vaccines and therapeutics for dengue, as already approved vaccines and therapeutics have limitations. DENGVAXIA is approved for use in children and teenagers who are 6–16 years of age and have confirmed dengue infection, while Takeda is approved for use in certain countries, and it has withdrawn its application for FDA approval.

show abstract

Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?

Cited by 24 publications

References 38 publications

Two decades of endemic dengue in Bangladesh (2000–2022): trends, seasonality, and impact of temperature and rainfall patterns on transmission dynamics

Two decades of endemic dengue in Bangladesh (2000–2022): trends, seasonality, and impact of temperature and rainfall patterns on transmission dynamics

Pre-dominance of dengue non-cross-reacting SARS-CoV-2 spike antibodies during the Omicron era and their role in the ADE-mediated surge of Dengue virus serotype 3

Tracing down the Updates on Dengue Virus—Molecular Biology, Antivirals, and Vaccine Strategies

Contact Info

Product

Resources

About